Black Diamond Therapeutics Maintains Buy Rating with $11 Price Target

TD Cowen analyst Marc Frahm maintains a Buy rating on Black Diamond Therapeutics, with a price target consensus of $11.00. The company's shares closed at $2.28. Frahm has a 6.0% average return and 42.90% success rate on recommended stocks. The analyst consensus is Moderate Buy.

Black Diamond Therapeutics Inc (BDTX), a biopharmaceutical company, has been a subject of interest among investors and financial professionals. The company's stock has been experiencing significant movement, with analysts providing varying insights into its future performance.

TD Cowen analyst Marc Frahm maintains a Buy rating on BDTX, with a price target consensus of $11.00. The company's shares closed at $2.28 on July 02, 2025. Frahm's track record includes a 6.0% average return and a 42.90% success rate on recommended stocks, contributing to the analyst consensus of Moderate Buy [1].

In addition to Frahm's analysis, Intellectia.ai provides a comprehensive stock price forecast for BDTX. The platform predicts a 1-day price of $3.18, a 1-week prediction of $3.17, and a 1-month forecast of $3.24. Looking further ahead, the 2026 projection estimates a value of $2.79, with a long-term 2030 forecast reaching $4.59 [2].

Intellectia.ai's evaluation includes five key dimensions: Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching, and Seasonality Analysis. The platform's analysis concludes that BDTX has several positive signals and is within a rising trend, making it a Strong Buy candidate [2].

The technical indicators lean more toward a Neutral outlook in the mid-term, with a downtrend starting from 2025-06-25. The total price change during this trend is +23.17%, indicating a potential rebound signal [2].

The company's short sell activity indicates that short sellers may be experiencing short cover, which could serve as an early warning of potential price increases [2].

In conclusion, while the current stock price of BDTX is relatively low, the positive signals and analyst ratings suggest that the stock may experience significant movement in the coming periods. However, investors should conduct thorough research and consider their risk tolerance before making investment decisions.

References:
[1] TD Cowen analyst Marc Frahm maintains a Buy rating on Black Diamond Therapeutics, with a price target consensus of $11.00. The company's shares closed at $2.28. Frahm has a 6.0% average return and 42.90% success rate on recommended stocks. The analyst consensus is Moderate Buy. [2] https://intellectia.ai/stock/BDTX/forecast